Seamus Fernandez
Stock Analyst at Guggenheim
(4.85)
# 71
Out of 5,182 analysts
128
Total ratings
64%
Success rate
56.61%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Buy | $1,163 → $1,183 | $874.00 | +35.35% | 25 | Apr 22, 2026 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $72 | $58.26 | +23.58% | 15 | Apr 8, 2026 | |
| GENB Generate Biomedicines | Initiates: Buy | $30 | $12.47 | +140.58% | 1 | Mar 24, 2026 | |
| APGE Apogee Therapeutics | Maintains: Buy | $130 → $160 | $85.37 | +87.42% | 9 | Mar 24, 2026 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $25 → $30 | $16.31 | +83.94% | 3 | Mar 19, 2026 | |
| TENX Tenax Therapeutics | Maintains: Buy | $25 → $34 | $14.60 | +132.88% | 4 | Mar 16, 2026 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $34 → $35 | $23.32 | +50.09% | 4 | Feb 27, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $140 → $143 | $84.18 | +69.87% | 4 | Feb 27, 2026 | |
| SGMT Sagimet Biosciences | Initiates: Buy | $27 | $8.75 | +208.57% | 1 | Feb 3, 2026 | |
| PCVX Vaxcyte | Reiterates: Buy | $116 | $58.73 | +97.51% | 5 | Feb 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $140 | $43.56 | +221.40% | 3 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $77 → $88 | $29.04 | +203.03% | 5 | Jan 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $45.95 | - | 1 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $11 | $5.01 | +119.56% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.87 | - | 4 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $25.89 | - | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $130 → $122 | $110.03 | +10.88% | 14 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $54.47 | - | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.74 | - | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $41.17 | - | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $145.50 | - | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.26 | - | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $54 | $4.22 | +1,179.62% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $45 | $33.23 | +35.42% | 3 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $36 → $38 | $186.68 | -79.64% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $35 → $38 | $26.48 | +43.50% | 3 | Jan 31, 2018 |
Eli Lilly and Company
Apr 22, 2026
Maintains: Buy
Price Target: $1,163 → $1,183
Current: $874.00
Upside: +35.35%
Bristol-Myers Squibb Company
Apr 8, 2026
Reiterates: Buy
Price Target: $72
Current: $58.26
Upside: +23.58%
Generate Biomedicines
Mar 24, 2026
Initiates: Buy
Price Target: $30
Current: $12.47
Upside: +140.58%
Apogee Therapeutics
Mar 24, 2026
Maintains: Buy
Price Target: $130 → $160
Current: $85.37
Upside: +87.42%
Amylyx Pharmaceuticals
Mar 19, 2026
Maintains: Buy
Price Target: $25 → $30
Current: $16.31
Upside: +83.94%
Tenax Therapeutics
Mar 16, 2026
Maintains: Buy
Price Target: $25 → $34
Current: $14.60
Upside: +132.88%
Arcutis Biotherapeutics
Feb 27, 2026
Maintains: Buy
Price Target: $34 → $35
Current: $23.32
Upside: +50.09%
Rhythm Pharmaceuticals
Feb 27, 2026
Maintains: Buy
Price Target: $140 → $143
Current: $84.18
Upside: +69.87%
Sagimet Biosciences
Feb 3, 2026
Initiates: Buy
Price Target: $27
Current: $8.75
Upside: +208.57%
Vaxcyte
Feb 2, 2026
Reiterates: Buy
Price Target: $116
Current: $58.73
Upside: +97.51%
Jan 20, 2026
Maintains: Buy
Price Target: $90 → $140
Current: $43.56
Upside: +221.40%
Jan 16, 2026
Maintains: Buy
Price Target: $77 → $88
Current: $29.04
Upside: +203.03%
Dec 9, 2025
Downgrades: Neutral
Price Target: n/a
Current: $45.95
Upside: -
Nov 18, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $5.01
Upside: +119.56%
Oct 23, 2025
Downgrades: Neutral
Price Target: n/a
Current: $8.87
Upside: -
Feb 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $25.89
Upside: -
Jan 17, 2025
Maintains: Buy
Price Target: $130 → $122
Current: $110.03
Upside: +10.88%
Oct 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $54.47
Upside: -
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.74
Upside: -
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $41.17
Upside: -
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $145.50
Upside: -
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $5.26
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $56 → $54
Current: $4.22
Upside: +1,179.62%
Mar 8, 2018
Maintains: Market Perform
Price Target: $60 → $45
Current: $33.23
Upside: +35.42%
Feb 6, 2018
Maintains: Market Perform
Price Target: $36 → $38
Current: $186.68
Upside: -79.64%
Jan 31, 2018
Maintains: Market Perform
Price Target: $35 → $38
Current: $26.48
Upside: +43.50%